Pharma BD Deal Intelligence

AstraZeneca PLC / Definiens AG

2014 · Acquisition/Merger · $150M · Complete

Announcement Sentiment

Strongly positive

AstraZeneca's MedImmune unit acquired private German digital-pathology firm Definiens for $150M upfront plus undisclosed milestones, gaining the Cognition Network Technology and Tissue Phenomics platform for biomarker-driven companion diagnostics across its immuno-oncology pipeline. Closed November 26, 2014.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Nov 04, 2014
Closed Nov 26, 2014
Deal value $150M
Deal type Acquisition/Merger
Therapeutic area Companion diagnostics across MedImmune oncology pipeline
Indications Companion diagnostics across MedImmune oncology pipeline
Key assets Tissue Phenomics tumor image-analysis platform (Cognition Network Technology)
Mechanism Computational pathology and biomarker image analysis

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals